SGNT Share Price

Open 21.74 Change Price %
High 21.76 1 Day 0.03 0.14
Low 21.74 1 Week 0.00 0.00
Close 21.76 1 Month 0.00 0.00
Volume 260421 1 Year 6.89 46.33
52 Week High 21.88
52 Week Low 10.55
SGNT Important Levels
Resistance 2 21.78
Resistance 1 21.77
Pivot 21.75
Support 1 21.75
Support 2 21.74
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.67 0.17%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OPXAW 0.01 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT)

SGNT Technical Analysis 5
As on 29th Aug 2016 SGNT Share Price closed @ 21.76 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 15.42 & Strong Buy for SHORT-TERM with Stoploss of 19.34 we also expect STOCK to react on Following IMPORTANT LEVELS.
SGNT Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
SGNT Other Details
Segment EQ
Market Capital 430829600.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.sagentpharma.com
SGNT Address
SGNT
1901 North Roselle Road
Suite 700
Schaumburg, IL 60195
United States
Phone: 847-908-1600
Fax: 847-908-1601
SGNT Latest News
Interactive Technical Analysis Chart Sagent Pharmaceuticals, Inc. ( SGNT NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Sagent Pharmaceuticals, Inc.
SGNT Business Profile
Sagent Pharmaceuticals, Inc. (Sagent) is an injectable pharmaceutical company, which develops and sources products, which the Company sells in the United States. The Company offers its customers a range of products across anti-infective, oncolytic and critical care indications in a range of presentations, including single- and multi-dose vials, pre-filled ready-to-use syringes, medical devices and premix bags, and it focuses to develop injectable products. As of December 31, 2010, it marketed 22 products, all of which were generic injectable products, and had a pipeline, which included 46 new products represented by 77 Abbreviated New Drug Applications (ANDAs), which either are under review by the United States Food and Drug Administration (FDA) or were approved and their associated products are pending commercial launch.